Ellansé Collagen Filler Singapore
Ellansé Collagen Filler
Ellanse collagen filler is a novel dermal filler used to treat wrinkles, volumise, sculpt and contour facial changes associated with ageing. Ellanse is also widely known as 少女针 in Singapore, Malaysia, Taiwan and Hong Kong. It works not only by correcting wrinkles under your skin, but also stimulates the production of your body’s own collagen. Ellanse collagen fillers are naturally absorbed in your body over time, and gives you natural long lasting results.
How does Ellanse Collagen Filler Work?
Collagen is an integral protein found within the skin. It maintains skin architecture by contributing to the skin’s elasticity, firmness and support.
Ellanse 少女针 is a biostimulating filler based on polycaprolactone (PCL) microspheres. It is the first filler to be based on PCL microspheres. Ellanse consists of non-cross linked 30% PCL microspheres and 70% carboxymethylcellulose (CMC) in a gel medium. CMC acts as a base to carry the active component which is PCL. Both PCL and CMC are bio-compatible and are naturally absorbed and excreted by the body. The PCL microspheres stimulates your own collagen and replaces the volume of the resorbed CMC based carrier after a few months.
What is Collagen?
There are thirteen types of collagen. The predominant types are:
- Type I Collagen: Skin, tendon, old scars
- Type II Collagen: Cartilage
- Type III Collagen: Blood vessels and recent scars
Type I Collagen is a protein found abundantly in skin tissue Collagen is secreted by skin cells, and has a triple helical structure. During youth, the collagen fibers are well organized, are produced abundantly and minimally degraded. With time, the collagen fibers become less organized, lesser quantity is produced and more is broken down by free radicals and enzymes.
Main treatment areas include:
Ellanse 少女针 is an excellent treatment to correct wrinkles, replace volume and sculpt your features naturally and beautifully.
- Laugh Lines
- Marionette Lines
Areas Not Recommended
As Ellanse collagen fillers are bio-stimulatory in nature, they are not recommended on certain parts of the face due to the risk of causing lumps when used under thinner skin. These areas include:
- Tear Trough (under eye)
How long will the results last?
The natural results of Ellanse Collagen Fillers lasts 1-4 years. Everybody is unique, Ellanse 少女针 treatments are tailored to the individual goals and results. There are currently 4 different options to choose from. During consultation, you will be advise on which filler will give you the best results.
How many sessions are needed?
Ellanse 少女针 is known for its longevity, and usually only one treatment session is needed. This makes Ellanse a cost effective treatment with long lasting natural results.
Post Procedure Effects of Ellanse Collagen Fillers
As with any filler injection, you may experience temporary injection site soreness, redness, swelling and bruising.
Ellanse is a semi-permanent filler, and cannot be easily reversed compared to hyaluronic acid based fillers. Uncommon side effects includes inadvertent injection into a blood vessel causing skin necrosis or even blindness. Good injection technique is key to minimize side effects associated with Ellanse filler injection.
After the Procedure
Ellanse is a popular treatment with minimal downtime.
It is recommended that you avoid vigorous exercise, alcohol and hot baths for at least 24 hours after the procedure.
Excessive sun exposure is to be avoided for at least one week; more than 2 weeks if you have a darker skin tone.
- Moers-Carpi M, Vogt S, Santos BM et al. A multicenter, randomized trial comparing calcium hydroxylapatite to two hyaluronic acids for treatment of nasolabial folds. Dermatol Surg 2007; 33(Suppl 2): S144–51.
- Nicolau PJ, Marijnissen-Hofst!e J. Neocollagenesis after injection of a polycaprolactone based dermal filler in a rabbit. Eur J Aesthet Med Dermatol 2013; 3: 19–26
- Moers-Carpi MM, Sherwood S. Polycaprolactone for the correction of nasolabial folds: a 24-month, prospective, randomized, controlled clinical trial. Dermatol Surg 2013; 39(3 Pt 1): 457–63.